Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Phlexglobal, providers of Trial Master File (TMF) technology and services solutions, and LUZ, a language translation company for life sciences, have entered into a partnership to offer a full eTMF and document translation solution.
read more
Tuesday, February 16, 2016
Philogen S.p.A. has entered into a second collaboration with AbbVie to discover and develop novel types of armed antibody products.
read more
Philogen announced a collaboration and license agreement with Boehringer Ingelheim to discover and optimize novel small molecule-based therapeutics using Philochem’s ESAC Library Technology platform.
read more
Philogen S.p.A has entered into a Service and Supply Agreement with IBSA (Institut Biochimique SA) to produce a recombinant therapeutic protein at Philogen GMP Facilities in Siena (Italy).
read more
Philogen S.p.A has entered into a Service and Supply Agreement with IBSA (Institut Biochimique SA) to produce a recombinant therapeutic protein at Philogen GMP Facilities in Siena (Italy).
read more
Phillips-Medisize announced an agreement with a leading biotechnology company to manufacture a wearable, electronic-enabled combination product.
read more
Wednesday, November 13, 2019
Phillips-Medisize announced the opening of a new GID center in Copenhagen, Denmark to support long-term growth plans for its advanced injection, wearable devices and connected health technologies.
read more
Tuesday, October 19, 2021
Phillips-Medisize, a Molex company and leader in the design and manufacture of drug delivery, diagnostic and MedTech devices, announces the expansion of its global manufacturing footprint, along with extended product design, development and ...
read more
Phillips-Medisize announced expansion of its current GID site in Struer, Denmark which is scheduled to open in the second quarter of 2020.
read more
Wednesday, February 20, 2019
Phillips-Medisize announced the groundbreaking of a new state of the art manufacturing facility located in the St. Croix Meadows development in Hudson, Wisconsin.
read more
Wednesday, September 22, 2021
PMI Global Services Inc announced that its offer for Vectura Group plc has become unconditional, having received valid acceptances for or acquired 74.77 % of Vectura shares, in excess of the 50% required under the acceptance condition, as well as ...
read more
Wednesday, August 03, 2016
Velocity Fund Partners, a Pittsburgh private equity company, has announced the acquisition of the Philadelphia clinical contract research organization (CRO) Indipharm and is relaunching the CRO as InClinica. Financial terms were not disclosed.
read more
Wednesday, November 08, 2023
Phesi, a leading provider of patient-centered data analytics, has enhanced its Trial Accelerator™ platform by introducing the Patient Access Score (PAS). This addition empowers clinical trial sponsors to pinpoint the most effective investigators.
read more
Thursday, September 26, 2024
Phesi has launched a self-service Investigator Site Profile solution designed to eliminate the non-active and non-enrolling investigator sites that development programs are typically burdened with. Investigator Site Profile leverages data from Phesi’...
read more
Phesi, a data-driven provider of premier integrated clinical development analytics products and services, today announced the appointment of Otis Johnson, PhD, MPA, as the company’s chief commercial officer. Dr. Johnson’s primary responsibility will ...
read more